COMMUNIQUÉS West-GlobeNewswire

Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights
16/03/2018
- Positive topline results from pivotal LEAP 1 trial announced in September 2017, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $86.9 million cash and investments as of December 31 [...]
Cannabis Wheaton Income Corp. Provides Update on the Initial Development of FV Pharma Inc. Facility
16/03/2018
VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX.V:CBW) (" Cannabis Wheaton " or the " Company ") is pleased to provide an update on the initial development of its [...]
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
16/03/2018
COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in [...]
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
16/03/2018
Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered [...]
Genesis HealthCare Reports Fourth Quarter and Fiscal Year End 2017 Results
16/03/2018
KENNETT SQUARE, Pa., March 16, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN ), one of the largest post-acute care providers in the United States, today announced operating results for [...]
Articles of Association
16/03/2018
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) Articles of Association most recently amended by the shareholders at the AGM held on 12 March 2018 ALKArticlesOfAssociation_12032018_final_approvedByAGM
Vistin Pharma ASA : Torbjørn Kjus joins Vistin to develop new business area
16/03/2018
Oslo, Norway, 16 March 2018 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) has entered into agreements with Torbjørn Kjus and Kenneth Tveter for the development of a new business area within energy trading activities. " [...]
Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne to Broaden the Applicability of the BREVAGenplus® Breast Cancer Risk Assessment Test
16/03/2018
MELBOURNE, Australia, March 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic [...]
DHAIS plc : Statement re Withdrawal from NEX Exchange
16/03/2018
16 March 2018 DHAIS PLC ("DHAIS" or "the Company") PROPOSED WITHDRAWAL FROM NEX EXCHANGE GROWTH MARKET DHAIS announces that the Company is today giving notice of its intention to withdraw its ordinary shares in the [...]
Probiodrug to present at 255th ACS National Meeting & Exposition
16/03/2018
Probiodrug to present at 255th ACS National Meeting & Exposition The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer's Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical [...]
argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies
16/03/2018
Grant to fund research of novel targets involved in regulation of locally-released TGF-beta, a protein active in immunosuppression March 16, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: [...]
Veloxis Increases Share Capital in Connection with Exercise of Warrants
16/03/2018
Company Release no. 04/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 16 March 2018 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company's [...]
Maple Leaf to Apply for a Dealer’s Licence with the Office of Controlled Substances within Health Canada
15/03/2018
CALGARY, Alberta, March 15, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) (TSXV:MGW) (OTCQB:MGWFF) is pleased to announce that it has engaged Cannabis Compliance Inc. (“ CCI [...]
Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update
15/03/2018
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018 [...]
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
15/03/2018
Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidance Plans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia, [...]
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
15/03/2018
VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]
Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents
15/03/2018
MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT ), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, [...]
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
15/03/2018
WARREN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported [...]
CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
15/03/2018
In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), please note that in the second bullet of the Corporate section, the end date of the non-exclusive [...]

Pages